Ligand Pharmaceuticals
LGND
261 hedge funds and large institutions have $1.67B invested in Ligand Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 70 increasing their positions, 111 reducing their positions, and 44 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
31.51% more ownership
Funds ownership: 106.9% → 138.42% (+32%)
0% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 44
2% less funds holding
Funds holding: 266 → 261 (-5)
29% less capital invested
Capital invested by funds: $2.37B → $1.67B (-$696M)
37% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 111
41% less call options, than puts
Call options by funds: $47.4M | Put options by funds: $80.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$62.7M |
| 2 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$57.8M |
| 3 |
SCM
Snyder Capital Management
San Francisco,
California
|
+$15.6M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$14.6M |
| 5 |
Millennium Management
New York
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$38.3M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$38.1M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$23.3M |
| 4 |
Janus Henderson Group
London,
|
-$20.5M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$17.5M |
LGND Hedge Fund Activity: Q1 2020 in Review
261 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2020, worth a combined $1.67B — down 29% from $2.37B a quarter earlier.
Fund positioning in LGND was balanced in Q1 2020: 44 funds opened new positions, 44 closed out, 70 added to existing stakes and 111 trimmed.
The largest buyer was Wasatch Advisors, opening a new position worth an estimated $62.7M. The largest seller was Renaissance Technologies, cutting an estimated $38.3M.
- 261 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2020, down from 266 in Q4 2019.
- Funds reported $1.67B of Ligand Pharmaceuticals stock for Q1 2020, down 29% quarter-over-quarter.
- 44 funds opened new Ligand Pharmaceuticals positions in Q1 2020 and 44 closed out, a net change of 0 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2020 was Wasatch Advisors, an estimated $62.7M added.
- The largest Ligand Pharmaceuticals seller in Q1 2020 was Renaissance Technologies, an estimated $38.3M sold.
Based on aggregated 13F filings for Q1 2020.